ArticleZeitschrift fur medizinische Physik2025
Advancing risk management in nuclear medicine diagnostic and therapy through incident-driven risk management tools.
Article in Zeitschrift fur medizinische Physik, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Application of an updated severity-based FMEA approach to Radiation Therapy QA: A multi-institutional exercise.Journal of applied clinical medical physics · 2026Article
- Theranostics in nuclear medicine: the era of precision oncology.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accidental or unintended exposures in nuclear medicine present significant risks, demanding proactive and systematic risk management strategies. This study explores the development and implementation of a novel software tool that integrates Failure Modes and Effects Analysis (FMEA) and Fault Tree Analysis (FTA) into a unified platform tailored for nuclear medicine. The tool addresses the complexities of risk assessment across diagnostic and therapeutic workflows, offering customizable templates and a streamlined process for identifying, prioritizing, and mitigating failure modes. A multicenter study involving nuclear medicine departments of various sizes demonstrated the tool's efficacy in standardizing risk analysis and enhancing interdisciplinary collaboration. Key scenarios, such as errors in radiopharmaceutical preparation and administration, were assessed, with rankings assigned based on a refined Risk Priority Number (RPN) system. The results underscore the transformative potential of combining FMEA and FTA in nuclear medicine, addressing the limitations of standalone methodologies. This approach improves workflow efficiency and ensures a robust framework for patient safety. Future directions include expanding the tool's applications, refining templates, and fostering a proactive culture of risk assessment. These advancements pave the way for safer, more efficient practices in nuclear medicine, benefiting patients and professionals alike.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.